Biora Therapeutics Q2 2024 GAAP EPS $(0.04) Beats $(0.45) Estimate, Sales $318.000K Up From $2.000K YoY
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics (NASDAQ:BIOR) reported a significant improvement in its Q2 2024 financial results, with a GAAP EPS of $(0.04) beating the $(0.45) estimate and sales increasing dramatically to $318.000K from $2.000K YoY.
August 12, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biora Therapeutics reported a GAAP EPS of $(0.04) for Q2 2024, significantly beating the analyst estimate of $(0.45). Sales also surged to $318.000K from $2.000K YoY.
The significant beat on EPS and the dramatic increase in sales are likely to positively impact BIOR's stock price in the short term. Investors will view the results as a strong indicator of the company's improving financial health.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100